I came across this question in a case book and was wondering what sort of opening structure would be best here, since the revenue changes by product segment are only presented to the candidate after the initial structure is presented. How would you go beyond revenues = qty x price for this question?
our client is a multinational pharmaceutical and biologics company. The client has a portfolio of drugs for major disease areas, including cancer, cardiovascular, and gastrointestinal diseases, to name a few. The client has experienced a decline in revenue over the last 18 months, and is fearful of further declines, especially given that its most commercially successful drug, which treats acid reflux disease, will be going off of patent in May of next year. What are the areas they should look into to change the course of this trend?